DNLI
Price
$14.87
Change
+$0.27 (+1.85%)
Updated
Apr 23 closing price
Capitalization
2.12B
19 days until earnings call
RARE
Price
$37.31
Change
+$1.40 (+3.90%)
Updated
Apr 23 closing price
Capitalization
3.37B
7 days until earnings call
Ad is loading...

DNLI vs RARE

Header iconDNLI vs RARE Comparison
Open Charts DNLI vs RAREBanner chart's image
Denali Therapeutics
Price$14.87
Change+$0.27 (+1.85%)
Volume$1.48M
Capitalization2.12B
Ultragenyx Pharmaceutical
Price$37.31
Change+$1.40 (+3.90%)
Volume$966.18K
Capitalization3.37B
DNLI vs RARE Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RARE commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and RARE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (DNLI: $14.87 vs. RARE: $37.31)
Brand notoriety: DNLI and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 102% vs. RARE: 112%
Market capitalization -- DNLI: $2.12B vs. RARE: $3.37B
DNLI [@Biotechnology] is valued at $2.12B. RARE’s [@Biotechnology] market capitalization is $3.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 4 bearish.
  • RARE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +18.49% price change this week, while RARE (@Biotechnology) price change was +6.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.04%. For the same industry, the average monthly price growth was -8.89%, and the average quarterly price growth was -12.57%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.37B) has a higher market cap than DNLI($2.12B). RARE YTD gains are higher at: -11.314 vs. DNLI (-27.036). RARE (-469M) and DNLI (-492.89M) have comparable annual earnings (EBITDA) . DNLI has more cash in the bank: 832M vs. RARE (610M). RARE has less debt than DNLI: RARE (40.3M) vs DNLI (48.7M). RARE has higher revenues than DNLI: RARE (560M) vs DNLI (0).
DNLIRAREDNLI / RARE
Capitalization2.12B3.37B63%
EBITDA-492.89M-469M105%
Gain YTD-27.036-11.314239%
P/E RatioN/AN/A-
Revenue0560M-
Total Cash832M610M136%
Total Debt48.7M40.3M121%
FUNDAMENTALS RATINGS
DNLI vs RARE: Fundamental Ratings
DNLI
RARE
OUTLOOK RATING
1..100
1513
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3998
PRICE GROWTH RATING
1..100
6479
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (74) in the Biotechnology industry is in the same range as DNLI (94). This means that RARE’s stock grew similarly to DNLI’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RARE’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for RARE (98). This means that DNLI’s stock grew somewhat faster than RARE’s over the last 12 months.

DNLI's Price Growth Rating (64) in the Biotechnology industry is in the same range as RARE (79). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as RARE (100). This means that DNLI’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRARE
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWSHX58.45N/A
N/A
American Funds Washington Mutual A
BRWVX21.36N/A
N/A
MFS Blended Research Growth Eq R6
FIDPX10.41N/A
N/A
Federated Hermes Intl Dividend Strategy
HMEZX19.77N/A
N/A
NexPoint Merger Arbitrage Z
FLKSX13.83N/A
N/A
Fidelity Low-Priced Stock K6

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.85%
BEAM - DNLI
59%
Loosely correlated
+3.87%
RCKT - DNLI
57%
Loosely correlated
+2.44%
NTLA - DNLI
56%
Loosely correlated
-2.65%
ARWR - DNLI
56%
Loosely correlated
+5.26%
RGNX - DNLI
56%
Loosely correlated
+13.43%
More